Compare Boston Scientific Corporation (BSX) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Paychex, Inc. — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Paychex, Inc. trades at $109.54 (market cap $38.95B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Paychex, Inc. pays a 4.35% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | PAYX | |
|---|---|---|
Market Cap | $66.37B | $38.95B |
Sector | Health | Industrials |
52-Week High | $108.14 | $147.99 |
52-Week Low | $42.63 | $85.57 |
Enterprise Value | $75.94B | $42.43B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Paychex (PAYX) trades at $110.75, up 2.98% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations, and maintains robust profitability with 27.03% net income margin. Recent dividend payment of $1.19 and positive business momentum from AI expansion and small business hiring trends support growth outlook.
Outlook remains positive with steady revenue growth and AI-driven efficiency gains, though valuation multiples appear elevated with P/E of 22.65. Risks include competitive pressures and macroeconomic sensitivity to small business employment trends. Analyst consensus is mixed with 16.67% buy ratings but price target alignment with current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
